Adamantane Resistance in Seasonal Human Influenza A Viruses from Calgary, Alberta (January 2007 to August 2008)

The available antivirals for the treatment and prophylaxis of influenza A infections include the adamantanes (amantadine and rimantadine), which are matrix (M2) protein inhibitors, and the neuraminidase inhibitors (oseltamivir and zanamivir). Resistance to the adamantanes is conferred by mutations a...

Full description

Saved in:
Bibliographic Details
Main Authors: Kanti Pabbaraju, Sallene Wong, Dmitri K Kits, Julie D Fox
Format: Article
Language:English
Published: Wiley 2010-01-01
Series:Canadian Journal of Infectious Diseases and Medical Microbiology
Online Access:http://dx.doi.org/10.1155/2010/710149
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832554982127173632
author Kanti Pabbaraju
Sallene Wong
Dmitri K Kits
Julie D Fox
author_facet Kanti Pabbaraju
Sallene Wong
Dmitri K Kits
Julie D Fox
author_sort Kanti Pabbaraju
collection DOAJ
description The available antivirals for the treatment and prophylaxis of influenza A infections include the adamantanes (amantadine and rimantadine), which are matrix (M2) protein inhibitors, and the neuraminidase inhibitors (oseltamivir and zanamivir). Resistance to the adamantanes is conferred by mutations at amino acid positions 26, 27, 30, 31 or 34 within the M2 protein of influenza A viruses. A significant increase in adamantane resistance has been reported worldwide since 2003, reflected by a similar increase in Canada. The present study reports on the frequency of adamantane resistance in seasonal influenza A viruses in Calgary, Alberta, for the period between January 2007 and August 2008, as an update to the previous report. Positive influenza A samples (221 original patient specimens and 34 isolates obtained by viral culture) were analyzed for changes in the critical amino acid residues of the M2 gene. The amplification and sequencing of regions that confer adamantane resistance directly from RNA extracts of clinical samples (without previous culture) makes this approach a fast and efficient process for monitoring resistance. The results showed that the frequency of resistance varied from 37.5% to 49.2% in circulating influenza A H3N2 virus strains (n=213) between January 2007 and April 2007. The frequency of resistance increased to 100% in May 2007, after which all H3N2 viruses were resistant until the end of the monitoring period. All resistant H3N2 viruses contained the serine to asparagine substitution at amino acid position 31. Resistance was not observed in the H1N1 viruses tested (n=39) within this monitoring period. The level of adamantane resistance in H3N2 viruses continues to remain high since resistant viruses became the prevalent circulating strains in 2005. Recent reports have indicated that the currently circulating swine-origin influenza A H1N1 subtype viruses are adamantane resistant. It is, thus, important to continue to monitor seasonal influenza A viruses for antiviral resistance markers to ensure optimal prophylaxis and treatment.
format Article
id doaj-art-fb136ac77254473c808ae2b7fdc5b483
institution Kabale University
issn 1712-9532
language English
publishDate 2010-01-01
publisher Wiley
record_format Article
series Canadian Journal of Infectious Diseases and Medical Microbiology
spelling doaj-art-fb136ac77254473c808ae2b7fdc5b4832025-02-03T05:49:55ZengWileyCanadian Journal of Infectious Diseases and Medical Microbiology1712-95322010-01-01212e87e9110.1155/2010/710149Adamantane Resistance in Seasonal Human Influenza A Viruses from Calgary, Alberta (January 2007 to August 2008)Kanti Pabbaraju0Sallene Wong1Dmitri K Kits2Julie D Fox3Provincial Laboratory for Public Health (Microbiology), Calgary, CanadaProvincial Laboratory for Public Health (Microbiology), Calgary, CanadaDepartment of Biological Sciences, University of Alberta, Edmonton, CanadaProvincial Laboratory for Public Health (Microbiology), Calgary, CanadaThe available antivirals for the treatment and prophylaxis of influenza A infections include the adamantanes (amantadine and rimantadine), which are matrix (M2) protein inhibitors, and the neuraminidase inhibitors (oseltamivir and zanamivir). Resistance to the adamantanes is conferred by mutations at amino acid positions 26, 27, 30, 31 or 34 within the M2 protein of influenza A viruses. A significant increase in adamantane resistance has been reported worldwide since 2003, reflected by a similar increase in Canada. The present study reports on the frequency of adamantane resistance in seasonal influenza A viruses in Calgary, Alberta, for the period between January 2007 and August 2008, as an update to the previous report. Positive influenza A samples (221 original patient specimens and 34 isolates obtained by viral culture) were analyzed for changes in the critical amino acid residues of the M2 gene. The amplification and sequencing of regions that confer adamantane resistance directly from RNA extracts of clinical samples (without previous culture) makes this approach a fast and efficient process for monitoring resistance. The results showed that the frequency of resistance varied from 37.5% to 49.2% in circulating influenza A H3N2 virus strains (n=213) between January 2007 and April 2007. The frequency of resistance increased to 100% in May 2007, after which all H3N2 viruses were resistant until the end of the monitoring period. All resistant H3N2 viruses contained the serine to asparagine substitution at amino acid position 31. Resistance was not observed in the H1N1 viruses tested (n=39) within this monitoring period. The level of adamantane resistance in H3N2 viruses continues to remain high since resistant viruses became the prevalent circulating strains in 2005. Recent reports have indicated that the currently circulating swine-origin influenza A H1N1 subtype viruses are adamantane resistant. It is, thus, important to continue to monitor seasonal influenza A viruses for antiviral resistance markers to ensure optimal prophylaxis and treatment.http://dx.doi.org/10.1155/2010/710149
spellingShingle Kanti Pabbaraju
Sallene Wong
Dmitri K Kits
Julie D Fox
Adamantane Resistance in Seasonal Human Influenza A Viruses from Calgary, Alberta (January 2007 to August 2008)
Canadian Journal of Infectious Diseases and Medical Microbiology
title Adamantane Resistance in Seasonal Human Influenza A Viruses from Calgary, Alberta (January 2007 to August 2008)
title_full Adamantane Resistance in Seasonal Human Influenza A Viruses from Calgary, Alberta (January 2007 to August 2008)
title_fullStr Adamantane Resistance in Seasonal Human Influenza A Viruses from Calgary, Alberta (January 2007 to August 2008)
title_full_unstemmed Adamantane Resistance in Seasonal Human Influenza A Viruses from Calgary, Alberta (January 2007 to August 2008)
title_short Adamantane Resistance in Seasonal Human Influenza A Viruses from Calgary, Alberta (January 2007 to August 2008)
title_sort adamantane resistance in seasonal human influenza a viruses from calgary alberta january 2007 to august 2008
url http://dx.doi.org/10.1155/2010/710149
work_keys_str_mv AT kantipabbaraju adamantaneresistanceinseasonalhumaninfluenzaavirusesfromcalgaryalbertajanuary2007toaugust2008
AT sallenewong adamantaneresistanceinseasonalhumaninfluenzaavirusesfromcalgaryalbertajanuary2007toaugust2008
AT dmitrikkits adamantaneresistanceinseasonalhumaninfluenzaavirusesfromcalgaryalbertajanuary2007toaugust2008
AT juliedfox adamantaneresistanceinseasonalhumaninfluenzaavirusesfromcalgaryalbertajanuary2007toaugust2008